Your browser doesn't support javascript.
loading
Impact of the Charlson Comorbidity Index on dose-limiting toxicity and survival in locally advanced and metastatic renal cell carcinoma patients treated with first-line sunitinib or pazopanib.
Demircan, Nazim C; Alan, Özkan; Basoglu Tüylü, Tugba; Akin Telli, Tugba; Arikan, Rukiye; Çiçek, Furkan C; Ercelep, Özlem; Öztürk, Mehmet A; Alsan Çetin, Ilknur; Ergelen, Rabia; Tinay, Ilker; Akgül Babacan, Nalan; Kaya, Serap; Dane, Faysal; Yumuk, Perran F.
Affiliation
  • Demircan NC; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
  • Alan Ö; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
  • Basoglu Tüylü T; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
  • Akin Telli T; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
  • Arikan R; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
  • Çiçek FC; Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey.
  • Ercelep Ö; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
  • Öztürk MA; Department of Internal Medicine, Division of Medical Oncology, Bahcesehir University Faculty of Medicine, Istanbul, Turkey.
  • Alsan Çetin I; Department of Radiation Oncology, Marmara University School of Medicine, Istanbul, Turkey.
  • Ergelen R; Department of Radiology, Marmara University School of Medicine, Istanbul, Turkey.
  • Tinay I; Department of Urology, Marmara University School of Medicine, Istanbul, Turkey.
  • Akgül Babacan N; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
  • Kaya S; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
  • Dane F; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
  • Yumuk PF; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.
J Oncol Pharm Pract ; 26(5): 1147-1155, 2020 Jul.
Article in En | MEDLINE | ID: mdl-31793376
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfonamides / Carcinoma, Renal Cell / Sunitinib / Kidney Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Oncol Pharm Pract Journal subject: FARMACIA Year: 2020 Type: Article Affiliation country: Turkey
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrimidines / Sulfonamides / Carcinoma, Renal Cell / Sunitinib / Kidney Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: J Oncol Pharm Pract Journal subject: FARMACIA Year: 2020 Type: Article Affiliation country: Turkey